NO. 17243CIP3(AP) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Applicant:

Serial No.:

Examiner:

Group Art Unit: 1626 ...

Filed:

For:

... I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Office of Initial Patent Examination, Customer Service Center, Washington, D.C. 20231 on:

> 20/01 Date of Deposit)

of Person

NOTICE OF CORRECTION OF FILING RECEIPT

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231

Chow et al.

09/815,362

March 21, 2001

COMPOUNDS AND METHOD OF

TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS

Not Yet Assigned

Dear Sir:

Please correct the filing receipt as follows:

Domestic Priority data as claimed by applicant

Delete "THIS APPLICATION IS A CON OF 09/329,752 06/10/1999 ABN" and insert in place thereof "THIS APPLICATION IS A CIP OF 09/329,752 06/10/1999 ABN"

If there is a fee associated with preparing this correction, please charge deposit account 01-0885.

Dated: ____

Telephone: (714) 246-4920 Facsimile: (714) 246-4249

Respectfully submitted

Carlos A. Fisher- T2-7P


Registration No. 36,510 Attorney of Record

ALLERGAN, INC.

Legal Department

2525 Dupont Drive

Irvine, CA. 92612



AUG 3 0 2001

TECH CENTER 1600 2001

COMMISSIONER AUGUST OFFICE
WASHINGTON. D. C. 20231

WASHINGTON, D.C. 20231 www.uspto.gov

UPDATED FILING RECEIPT

ÇĞD0000006414898°

FIL FEE REC'D ATTY DOCKET NO DRAWINGS TOT CLAIMS IND CLAIMS GRP ART UNIT FILING DATE APPLICATION NUMBER 17243CIP3 108 2 4656

03/21/2001 1626 09/815,362

CONFIRMATION NO. 4078

Carlos A. Fisher ALLERGAN, INC. T2-2E 2525 Dupont Drive

Date Mailed: 08/13/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE. NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Irvine, CA 92623

Ken Chow, Newport Coast, CA: Daniel W. Gil, Corona Del Mar, CA; James A. Burke, Santa Ana, CA; Dale A. Harcourt, Irvine, CA; Michael E. Garst, Newport Beach, CA; Larry A. Wheeler, Irvine, CA;

Assignment For Published Patent Application

ALLERGAN SALES, INC.;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/329,752 06/10/1999 ABN WHICH IS A CIP OF 09/205,597 12/04/1998 ABN WHICH IS A CIP OF 08/985,347 12/04/1997 ABN

Foreign Applications

If Required, Foreign Filing License Granted 06/29/2001

Projected Publication Date: 11/22/2001

Non-Publication Request: No

CC: CPI: 8-17.2001

Early Publication Request: No

Title

Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors

Preliminary Class

548

Data entry by : LE, HANH

Team: OIPE

Date: 08/13/2001

THE CONTRACT OF THE PROPERTY O

RESPONSE DUE March 21 2002 ACTION CIP Hoseign Filey The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the
 title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231